18F-DOPA II - PET Imaging Optimization

A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2. Pediatric patients (less than 18 years old) with neuroblastoma. 3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor. 4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia. 5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain t

Trial Details

NCT ID
NCT04706910
Phase
PHASE3
Sponsor
University of Alberta
Status
RECRUITING
Cancer Type
Brain Cancer
Locations (sample)
  • Edmonton, Alberta, Canada

Key Eligibility Criteria

  • Pediatric patients (less than 18 years old) with congenital hyperinsulinism.
  • Pediatric patients (less than 18 years old) with neuroblastoma.
  • Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor.
  • Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →